Skip to content

L · 0SAN.L · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Sandoz Group AG (0SAN.L) intrinsic value and stock valuation

$80.50as of 2026-11-21 · Mkt cap 27.79B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Sandoz Group AG DCF and intrinsic value

InvestorsCraft values 0SAN.L with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from 0SAN.L’s statements →

Sandoz Group AG Graham Number

Graham Number: $32.54d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Rotkreuz 6343 sandoz.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$11.6B+5.1% 5y CAGRd
20202025
Net income
$957.5M+17.2% 5y CAGRd
20202025
Free cash flow
$1.15B+9.9% 5y CAGRd
20202025
Total equity
$9.38B+6.6% 5y CAGRd
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$11.6B$10.4B$9.98B$8.86B$8.79B
Operating income$1.79B$307M$375M$1.33B$1.38B
Net income$957.5M$1M$77M$809.9M$830.2M
EPSd$2.19M$2.32K$178.6K$1.88M$1.93M
Operating cash flow$1.67B$656M$362M$1.17B$1.24B
Capital expenditure-$-516.45M-$-596M-$-625M-$-407.81M-$-382.16M
Free cash flow$1.15B$60M-$-263M$760.2M$855.8M
Total assets$22B$19.9B$19.4B$16.2B$16B
Total debt$5.68B$4.85B$4.55B$309M$284.3M
Net debt$3.94B$3.66B$3.44B$240.6M$247.8M
Total equity$9.38B$8.16B$8.65B$8.1B$7.44B
Cash and short-term investments$1.74B$1.19B$1.11B$68.4M$36.5M
Income statement
20252024202320222021
Revenue$11.6B$10.4B$9.98B$8.86B$8.79B
Cost of revenue$6.15B$5.46B$5.42B$4.71B$4.64B
Gross profit$5.46B$4.93B$4.56B$4.15B$4.15B
Research and development expenses$1.1B$932M$926M$795.6M$832.9M
Selling, general and administrative expenses$2.65B$2.43B$2.39B$2.03B$1.94B
Other expenses-$-74.38M$1.25B$874M-$-8.6M-$-6.4M
Operating expenses$3.67B$4.62B$4.19B$2.82B$2.77B
Cost and expenses$9.83B$10.1B$9.6B$7.52B$7.41B
Interest income$0.00$37.9M$27.9M$7.64M$4.57M
Interest expense$230.5M$235.1M$177.9M$84.1M$61.3M
Depreciation and amortization$0.00$502M$525M$437.4M$406.9M
Ebitda$1.79B$742M$857M$1.57B$1.68B
Operating income$1.79B$307M$375M$1.33B$1.38B
Total other income/expenses, net-$-521.69M-$-318M-$-245M-$-281.74M-$-179.2M
Income before tax$1.26B-$-11M$130M$1.05B$1.2B
Income tax expense$306.9M-$-12M$50M$233M$368.5M
Net income$957.5M$1M$77M$809.9M$830.2M
Weighted average shares outstanding$431.1M$429.9M$429.9M$431M$431M
Weighted average diluted shares outstanding$436.8M$431.2M$431.2M$431M$431M
Balance sheet
20252024202320222021
Cash and short-term investments$1.74B$1.19B$1.11B$68.4M$36.5M
Net receivables$3B$3.15B$3.03B$3.23B$2.99B
Inventory$2.84B$2.8B$2.7B$1.97B$1.83B
Total current assets$8.16B$7.8B$7.57B$5.53B$5.07B
Property, plant and equipment, net$2.78B$1.99B$1.85B$1.76B$1.76B
Goodwill and intangible assets$9.87B$8.94B$9.15B$6.88B$7B
Long-term investments$40M$44.4M$22.7M$20.4M$21M
Total non-current assets$13.9B$12.1B$11.9B$10.7B$10.9B
Total assets$22B$19.9B$19.4B$16.2B$16B
Accounts payable$1.85B$1.52B$1.59B$1.02B$1.01B
Short-term debt$672.6M$187M$323M$3.76B$4.4B
Deferred revenue$13M$0.00$0.00$2.78M$3.64M
Total current liabilities$6.89B$6.31B$5.7B$7.32B$7.62B
Long-term debt$5.01B$4.67B$4.23B$109.1M$109.5M
Deferred revenue, non-current$0.00$0.00$0.00$81.4M$93.9M
Total non-current liabilities$5.75B$5.44B$5.08B$817M$923.9M
Capital lease obligations$314.8M$334M$309M$110M$125M
Total liabilities$12.6B$11.7B$10.8B$8.13B$8.55B
Common stock$25M$25M$24M$100K$0.00
Retained earnings$8.61B$7.18B$6.78B-$-20K$7.52B
Accumulated other comprehensive income (loss)$739.5M$209.6M$473.9M-$-159.13M-$-94.76M
Total equity$9.38B$8.16B$8.65B$8.1B$7.44B
Total investments$40M$44.4M$22.7M$20.4M$21M
Total debt$5.68B$4.85B$4.55B$309M$284.3M
Net debt$3.94B$3.66B$3.44B$240.6M$247.8M
Cash flow statement
20252024202320222021
Net income$957.5M$1M$80M$850M$830.2M
Depreciation and amortization$570.9M$502M$525M$437.4M$447.1M
Stock-based compensation$0.00$88M$25M$0.00$0.00
Change in working capital$904.1M-$-365M-$-663M-$-36M-$-57.6M
Accounts receivable-$-107.9M$256M-$-271.39M-$-170M-$-67.66M
Inventory$237.8M-$-277M-$-519.42M-$-259.78M$161.8M
Accounts payable$29.3M$22M$456.5M$125.1M$85M
Net cash provided by operating activities$1.67B$656M$362M$1.17B$1.24B
Investments in property, plant and equipment-$-828.63M-$-404M-$-567.95M-$-407.81M-$-382.16M
Acquisitions, net-$-265.04M-$-182M-$-18M-$-28.65M-$-305.36M
Net cash used for investing activities-$-1.03B-$-740M-$-614M-$-410.68M-$-631.76M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased$0.00-$-12M$0.00$0.00$0.00
Dividends paid-$-329.99M-$-215M$0.00$0.00$0.00
Net cash used for financing activities-$-206.37M$242M$1.24B-$-734.45M-$-600.67M
Net change in cash$376.4M$82M$1.04B$32M$1.97M
Cash at end of period$1.74B$1.19B$1.11B$68.5M$36.5M
Operating cash flow$1.67B$656M$362M$1.17B$1.24B
Capital expenditure-$-516.45M-$-596M-$-625M-$-407.81M-$-382.16M
Free cash flow$1.15B$60M-$-263M$760.2M$855.8M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sandoz Group AG

        Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.

        CEO
        Richard Saynor
        Employees
        22.05K
        Beta
        0.53

        Explore

        Frequently asked questions

        What is the intrinsic value of Sandoz Group AG (0SAN.L)?

        InvestorsCraft does not currently publish an intrinsic value for 0SAN.L. How the IC value is calculated.

        Is 0SAN.L undervalued?

        InvestorsCraft does not publish an undervaluation signal for 0SAN.L at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.